Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | F11 | P03951 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1851608 | 0.80 | LPL (0.41) | LPLLIPGP2RX7CA1CA2 | |
| SCHEMBL2656259 | 0.74 | LPL (0.37) | LPLLIPGP2RX7 | |
| SCHEMBL3529326 | 0.74 | LPL (0.37) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL4497626 | 0.73 | LPL (0.58) | LPLLIPG | |
| SCHEMBL793512 | 0.72 | LPL (0.41) | LPLLIPGP2RX7CA1CA2 | |
| SCHEMBL12703333 | 0.72 | LPL (0.42) | LPLLIPGP2RX7CA1CA2 | |
| SCHEMBL26621977 | 0.71 | LPL (0.35) | LPLLIPG | |
| SCHEMBL16816598 | 0.71 | LPL (0.38) | LPLLIPG | |
| SCHEMBL31653199 | 0.70 | KMT2A (0.44) | MAPK1 | |
| SCHEMBL14727554 | 0.69 | LPL (0.43) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577245-B2 | Sulfonyl benzamide derivatives as Bcl-2 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2026-03-17 | — | — | US | disclosed |
| US-20240166644-A1 | SULFONYL BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2024-05-23 | — | — | US | disclosed |
| EP-4298098-A1 | SULFONYL BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2024-01-03 | — | — | EP | disclosed |
| US-11851425-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines | H. LUNDBECK A/S (DK) | 2023-12-26 | — | — | US | disclosed |
| CN-114835704-B | Sulfonylbenzamide derivatives as BCL-2 inhibitors | 苏州亚盛药业有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-111556871-B | 1H-pyrazolo [4,3-b ] pyridines as PDE1 inhibitors | H.隆德贝克有限公司 | 2023-07-07 | — | — | CN | disclosed |
| US-11634416-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines | H. LUNDBECK A/S (DK) | 2023-04-25 | — | — | US | disclosed |
| CN-110099901-B | Pyrazolo [3,4-b ] pyridines and imidazo [1,5-b ] pyridazines as PDE1 inhibitors | H.隆德贝克有限公司 | 2023-01-03 | — | — | CN | disclosed |
| US-11491140-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2022-11-08 | — | — | US | disclosed |
| CN-111465410-B | Combination therapy comprising administration of 1H-pyrazolo [4,3-B ] pyridine | H.隆德贝克有限公司 | 2022-10-25 | — | — | CN | disclosed |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-28 | — | — | US | disclosed |
| WO-2007048088-A2 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007048088-A2 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2006138155-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | WO | disclosed |
| US-20060281788-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
| WO-2006102194-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20060189623-A1 | Inhibitors of c-fms kinase | ILLIG CARL R | 2006-08-24 | — | — | US | disclosed |
| US-20060148812-A1 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-06 | — | — | US | disclosed |
| WO-2006047277-A2 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189623-A1 | Inhibitors of c-fms kinase | MUSK, TYK2, FES | LPL 4029/4885LIPG 2439/4885P2RX7 994/4885 |
| US-12577245-B2 | Sulfonyl benzamide derivatives as Bcl-2 inhibitors | BCL2A1, BCL2L1, BCL2L11 | LPL 1842/4885LIPG 1892/4885P2RX7 3804/4885 |
| US-20060281788-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | FLT3, MCL1, CSF1R | LPL 3554/4885LIPG 2118/4885P2RX7 4454/4885 |
| US-11851425-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines | PDE3B, PDE1B, PDE12 | LPL 3114/4885LIPG 4327/4885P2RX7 140/4885 |
| US-11491140-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | PDE3A, PDE5A, PDE12 | LPL 2346/4885LIPG 3666/4885P2RX7 305/4885 |
| US-11634416-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines | PDE1B, PDE3B, PDE1A | LPL 3316/4885LIPG 4670/4885P2RX7 245/4885 |
| US-20060148812-A1 | Inhibitors of c-fms kinase | MUSK, TYK2, FES | LPL 4029/4885LIPG 2439/4885P2RX7 994/4885 |
| US-20240166644-A1 | SULFONYL BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | LPL 1378/4885LIPG 990/4885P2RX7 4438/4885 |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | FLT3, PLK1, PHKG1 | LPL 4651/4885LIPG 3295/4885P2RX7 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.